Neutron-OD

Treatment option:

Medically reviewed

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neutron-OD

Property	Description
Active Ingredients	Pregabalin, Mecobalamin (Methylcobalamin)
Form	Oral Tablet (Extended-Release/OD)
Pharmacological Class	Anticonvulsant & Nutritional Supplement Combination
General Purpose	Management of chronic nerve discomfort and support for nerve health
Origin	Blend of a Synthetic and a Vitamin derivative

Defining the Combination Medicine

Neutron-OD is a prescription combination medicine categorized as an analgesic and generally used to manage chronic discomfort associated with nerve-related conditions, such as nerve-related pain in diabetic patients. It is an oral pharmaceutical product designed to deliver two distinct active ingredients simultaneously to address both symptomatic nerve activity and nerve health support. This dual composition places it within the pharmacological class of agents that combine an anticonvulsant action with a nutritional supplement role for managing conditions where both nerve pain and nerve damage coexist. The medicine is typically provided as a tablet bearing the OD suffix, which signifies an extended-release formulation, designed to provide consistent drug levels and support convenient once-daily dosing.

Composition and Origin of Active Ingredients

The two core active ingredients in Neutron-OD are Pregabalin and Mecobalamin. Pregabalin is a synthetic compound classified as a Gabapentinoid, which acts by modulating nerve signaling in the central nervous system. Mecobalamin (Methylcobalamin) is the biologically active coenzyme form of Vitamin B12 and is essential for neurological function. Unlike less active B12 forms, Mecobalamin is the specific form required by nerve cells for key metabolic functions. The inclusion of Mecobalamin ensures the body receives the coenzyme in a readily usable state for nerve support, a composition feature that distinguishes the therapeutic profile of this formulation.

General Purpose of the Dual-Action Approach

The general purpose of the Neutron-OD formulation is to achieve simultaneous symptomatic relief and support for long-term neurological health. The Pregabalin component primarily works by reducing the excessive signaling activity of overactive nerves, which helps mitigate chronic discomfort. Simultaneously, the Mecobalamin component provides essential cofactors to support the metabolic function and structural integrity of the nerve cells. The combined action aims to stabilize nerve function while promoting the body's natural processes for nerve maintenance and repair in combination therapy.

Regulatory References

What side effects are possible with Neutron-OD?

Possible side effects and safety information

The safety profile of Neutron-OD is largely determined by its Pregabalin component, an anticonvulsant agent whose effects are primarily observed in the central nervous system (CNS). Official regulatory documents categorize adverse reactions based on their frequency of occurrence and the physiological systems affected.

Frequency-Classified Adverse Reactions

Adverse reactions classified as Very Common (occurring in ge 1/10 patients) include Dizziness and Somnolence (sleepiness). Common effects (ge 1/100 to <1/10 patients) listed in regulatory documents include Headache, Fatigue, Blurred vision, Weight increased, and Constipation. Effects on organ systems are classified to include Nervous System Disorders, Psychiatric Disorders (e.g., confusion, euphoric mood), and Metabolism and Nutrition Disorders (e.g., increased appetite, weight gain).

Serious Adverse Reactions and Safety Constraints

Official prescribing information documents rare but serious adverse reactions, which include Angioedema (severe swelling due to hypersensitivity) and the reported risk of Suicidal Ideation and Behavior associated with the anti-epileptic drug class. Severe Respiratory Depression is also noted, particularly when Pregabalin is used alongside other CNS depressants. The Mecobalamin (Vitamin B12) component is generally associated with a very favorable safety profile.

Population and Exposure Considerations

The drug's official safety profile establishes specific constraints based on elimination, noting that Pregabalin clearance is directly proportional to renal function. Therefore, dose adjustments are required for patients with renal impairment. The most common effects, Dizziness and Somnolence, are officially noted as being more frequently observed early in treatment or following dose escalation. Furthermore, withdrawal reactions may occur upon rapid discontinuation, as noted in regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with the active component Pregabalin is primarily associated with Central Nervous System (CNS) effects. Documented clinical signs in acute high-dose exposure include somnolence, a confusional state, agitation, restlessness, and ataxia (incoordination). Gastrointestinal symptoms like nausea and vomiting have also been reported in regulatory sources.

Immediate medical attention is required for suspected overdose or the manifestation of severe symptoms. Regulators mandate seeking urgent help, including contacting a Certified Poison Control Center, when signs of life-threatening events occur. These severe outcomes may include respiratory depression, heart block, or Angioedema (swelling of the face, mouth, or throat), which can critically compromise breathing.

Population-specific considerations noted in official labeling indicate an increased risk of severe outcomes for elderly patients and those with preexisting respiratory impairment. Patients with impaired renal function are noted to be at risk of increased toxicity and may require specific management.

The official regulatory documents state that no specific antidote is known for this overdose. Management consists of providing symptomatic and supportive treatment. Procedural options such as gastric lavage may be used for unabsorbed substance, and hemodialysis may be necessary for elimination in patients with significantly impaired renal function.

Therapeutic Uses of Neutron-OD

What Neutron-OD Treats: Main Uses and Benefits

Neutron-OD is used to provide supportive assistance across several symptomatic domains. It is often applied in contexts where short-term symptomatic assistance is needed. The medicine is relevant when symptoms intensify or create noticeable interference with a patient’s daily stability.

Managing Acute Symptomatic Discomfort

This medicine is commonly used to help with situations involving symptoms related to physical discomfort or other acute manifestations that may appear suddenly or intensify rapidly. It is relevant for easing symptoms related to physical discomfort, systemic imbalance, or heightened physiological activity. It supports the patient during difficult episodes by easing distress and may assist with temporary symptom stabilization.

Supporting Functional Stability During Episodes

Neutron-OD is considered relevant when symptom clusters create noticeable functional strain or interfere with routine activities. It provides supportive relief that assists with maintaining functional stability, helping patients cope more steadily when symptoms are more noticeable. It is applied across domains where additional symptomatic support is needed.

Quick Fact: Used for Fluctuating Symptoms

Addressing Episodic and Fluctuating Symptoms

It is generally used across conditions presenting with acute episodes characterized by periods of heightened symptoms or increased physiological tension. The medication contributes to easing the overall symptom load during temporary symptomatic phases.

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility for Neutron-OD, based strictly on government regulatory documents, such as Prescribing Information (US FDA) or the Summary of Product Characteristics (EU EMA).

Populations for Whom Use is Prohibited or Restricted

Category	Regulatory Status
Absolute Contraindication	Use is prohibited for patients with known hypersensitivity to the active substance or any component of the drug. Use is also contraindicated in patients with Leber's disease (hereditary optic nerve atrophy) due to the risk of severe vision loss.
Age-Related	Use in children and adolescents (<18 years) is generally not established due to insufficient data on safety and effectiveness in the pediatric population.
Pregnancy/Lactation	Use is not recommended in pregnant or breastfeeding women. Safety has not been adequately established in these populations, requiring a strict risk-benefit assessment by a healthcare provider.

Condition-Specific Limitations

Regulatory labeling requires caution and potential dose modification in patients with severe renal impairment (kidney disease). Use is also subject to special precaution in individuals with pre-existing, non-compensated severe hepatic impairment (liver disease) or active gastrointestinal disease.

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The interaction profile of Neutron-OD, which contains Pregabalin and Mecobalamin, is documented by regulatory authorities based on pharmacodynamic potentiation and specific pharmacokinetic constraints.

Pharmacodynamic Interactions and Restrictions

Co-administration of the Pregabalin component with Central Nervous System (CNS) depressants, such as Oxycodone or Lorazepam, results in a documented additive impairment of motor and cognitive function. This pharmacodynamic potentiation also occurs with the co-ingestion of Ethanol (Alcohol), which increases the severity of dizziness and sleepiness. An increased risk of peripheral edema and weight gain is officially noted when Pregabalin is used alongside certain antidiabetic agents (e.g., Pioglitazone, Rosiglitazone).

Absorption and Contraindications

Due to the Mecobalamin component, the medicine is strictly contraindicated in individuals with Leber's Disease (hereditary optic nerve atrophy) because of the risk of severe optic nerve damage. Furthermore, specific medicines like antacids and certain antibiotics are documented to interfere with the absorption of Mecobalamin.

Pharmacokinetic and Population Notes

The extended-release formulation is subject to the regulatory instruction that food decreases the rate of Pregabalin absorption, leading to a reduction in peak plasma concentration (Cmax) by 25–30%. Pregabalin undergoes negligible metabolism. Given that clearance is substantially dependent on renal excretion, the official regulatory documentation states that the risk of toxic reactions is greater in patients with impaired renal function, including the elderly.

Mechanism of Action

The mechanism of Neutron-OD is defined by a dual action that combines the modulation of abnormal nerve signaling with metabolic factor provision for nerve structural elements. This approach targets two distinct, yet coordinated, physiological domains to influence nerve function.

Modulating Pathological Nerve Signaling

This domain describes how the Pregabalin component works by engaging the alpha2delta (alpha-2-delta) subunit of Voltage-Gated Calcium Channels on presynaptic nerve terminals. Binding to this subunit functionally reduces the influx of calcium ions, a critical step for nerve signal transmission. By limiting calcium entry, the drug decreases the release of excitatory neurotransmitters (like Glutamate and Substance P) in the CNS, leading to a physiological reduction of hyperactivity within nerve pathways and the suppression of abnormal signal transmission.

Cofactor Action on Neurological Structure and Metabolism

The second domain involves the Mecobalamin component, the active coenzyme form of Vitamin B12, which acts as an essential cofactor for the enzyme Methionine Synthase. This enzyme facilitates the synthesis of molecules, such as SAM, that are required for key cellular processes. This coenzyme action facilitates the production of myelin sheath phospholipids and proteins required for the assembly of physical components of nerve fibers and supporting cellular processes. This mechanism influences intrinsic biological processes governing the structural components and metabolic function of nerve cells.

Dosage and Administration Information

How Neutron-OD is Used: Official Administration Guidelines

Neutron-OD is an Oral Tablet formulated for extended-release delivery, designed to be administered once daily (OD). The use of this combination medicine is defined by guidelines pertaining to its administration route, dosage titration, and specific handling requirements.

Dosing Schedule and Administration Method

The medicine is taken orally, typically after an evening meal, and must be swallowed whole. It is explicitly documented that the tablet should not be split, crushed, or chewed to avoid compromising the controlled-release mechanism.

Initial Dosing: Treatment generally begins with a low dose of the Pregabalin component, such as 75 mg or 165 mg once daily.
Titration and Maintenance: The dose is progressively increased (titrated) within the first week to a standard maintenance range, which for the Pregabalin component is commonly 150 mg to 330 mg once daily, according to established titration schedules.
Maximum Dose: The maximum recommended daily intake of the Pregabalin component in the extended-release form is 330 mg for most approved uses, although higher doses are specified for certain conditions in some regions.

Adjustments and Procedural Conditions

Procedural Feature	Standard Procedure
Timing in Relation to Meals	Recommended to be taken after an evening meal.
Missed Dose Rule	If the evening dose is missed, take it at bedtime following a snack; if missed until morning, take it following the morning meal, then resume the usual evening schedule. Do not take two doses at the same time.
Renal Impairment	Dose adjustment is mandatory for patients with reduced kidney function (creatinine clearance less than 60 mL/min). Dosage must be reduced based on the degree of renal impairment.
Discontinuation	The medicine should not be stopped abruptly; instructions require the dose to be tapered gradually over a minimum of one week.

These instructions define the procedural structure for using Neutron-OD, ensuring consistent drug delivery and adherence to established protocols.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Neutron-OD

Evidence for Use in Peripheral Neuropathic Pain (NP)

This section summarizes the structure of research, including Randomized Comparative Studies and Observational Reports, that have investigated the combination medicine's use in studies for Peripheral Neuropathic Pain (NP), including research for Diabetic Peripheral Neuropathy (DPN).

Research has explored this combination in Adults who had been studied for neuropathic pain. Studies were conducted during periods of increased symptom activity, and researchers monitored patient-reported outcomes describing perceived discomfort and examined outcomes related to symptom intensity using various measurement scales.

Studies describe what has been observed so far in terms of changes measured during the study period when the combination was studied in the context of nerve discomfort. However, long-term outcomes are not fully established by the research. Follow-up durations were limited in many of the key studies, and results apply only to the populations studied.

Evidence for Symptomatic Relief and Nerve Health Support

This block describes the studies, such as Open-Label Trials and Prospective Studies, that explored the dual-action approach of the medication in studies of episodic symptoms and research examining the nutritional component in outcomes related to physiological maintenance.

Research scenarios involving fluctuating or unstable symptoms were used in studies focusing on episodes where symptoms become more noticeable. Research examined outcomes related to systemic or functional imbalance, using patient reports and physician assessments to monitor outcomes related to daily functioning or activity level.

Studies reported variability when trying to isolate the specific contribution of the nutritional component to rapid symptom changes. Comparative evidence against single-ingredient treatment, focusing on long-term functional outcomes, remains limited. The evidence quality varies across studies, and certainty remains low in certain areas.

Long-Term Research and Follow-up Durations

Research exploring short-term symptom changes typically monitored responses over defined time intervals of 2 to 12 weeks. While some observational research has extended to six months or longer, these longer durations are not available for all the core comparative studies of the specific combination product. Sustained observation of effects over years remains limited, and long-term outcomes are not fully established.

What Is Still Uncertain About Neutron-OD's Research

Several areas of uncertainty exist within the evidence landscape. Follow-up durations were limited in many trials, and comparative evidence against other combination treatments is often lacking. The contribution of the nutritional component to overall long-term physiological outcomes is one area where data are still emerging. Existing studies provide limited insight into the patterns of change for the combination over many years in conditions characterized by fluctuating or episodic manifestations.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Neutron-OD (FAQ)

Q: When is the best time of day to take Neutron-OD?

The timing of Neutron-OD often depends on the prescribed strength and may be taken with a meal. This association with food is often suggested because it may help ensure the drug is absorbed as intended.

For the 10 mg dose, patients are generally told they can take it with or without food. However, for the 15 mg and 20 mg doses, it is generally recommended to take them with food, as instructed in the product labeling. Taking the medicine at the same time every day is typically recommended to maintain a steady level in the blood.

Q: What should I do if I miss a dose?

Dosing instructions for a missed dose vary based on the specific regimen (once-daily or twice-daily).

Once-Daily Regimen: Official guidance often instructs patients to take the dose as soon as it is remembered that same day.
Twice-Daily Regimen: For twice-daily regimens, the instructions from the healthcare provider or labeling typically advise taking the missed dose immediately, potentially resulting in two doses on the same day.

Patients are generally advised not to double the dose to make up for a missed one the next day, as this is associated with a risk of bleeding. Consulting a healthcare provider after missing a dose is often recommended.

Q: Can I take Neutron-OD if I have kidney problems?

Neutron-OD can be used in individuals with some degree of kidney problems, but caution is advised, as kidney function is important for clearing the drug from the body.

In patients with severe kidney impairment, the risk of bleeding is significantly higher, and the regulatory information indicates it may not be recommended or a dose adjustment may be necessary. A healthcare provider typically uses blood tests to assess kidney function and determine the appropriate dosage regimen for the patient's condition.

How should Neutron-OD be stored and disposed of?

How to Store and Dispose of Neutron-OD

The storage and disposal of Neutron-OD (Pregabalin/Mecobalamin tablets) must strictly follow regulatory guidance to maintain product stability and safety.

Storage Requirements

Temperature: Store at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F). Avoid freezing and excessive heat.
Protection: Keep the medication out of the sight and reach of children. The product must be protected from light and moisture and kept in its original, tightly closed container.

Disposal Instructions

Unused or expired Neutron-OD should be disposed of according to local regulations. Patients are advised to utilize a drug take-back program when available. To prevent accidental ingestion or environmental contamination, do not flush the tablets down the toilet or discard them in household trash unless first mixed with an undesirable substance, such as dirt or used coffee grounds, and sealed in a plastic bag.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

India

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z